A Food-Effect Study for the Safety and Assessment of Pharmacokinetics of Navocaftor and Galicaftor
Latest Information Update: 13 Jan 2023
At a glance
- Drugs Galicaftor (Primary) ; Navocaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms M23-492 FE
- Sponsors AbbVie
- 10 Jan 2023 Status changed from active, no longer recruiting to completed.
- 18 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2022 Status changed from not yet recruiting to recruiting.